![Inside Honeywell’s plan for a new F-35 cooling system [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/07/8509355-1-scaled-e1721820217290.jpg?#)
Bristol Myers bolsters radiopharma portfolio with PhiloChem deal
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.
